Enodia Therapeutics

French tech company | Builders Republic

About

Drug-discovery biotech developing small-molecule degraders that eliminate disease-driving proteins at the point of synthesis — selectively blocking the cellular gateway that proteins pass through as they are made, redirecting them for destruction, using a proteomics- and machine-learning-driven platform spun out of Institut Pasteur and built by Argobio, with a pipeline in inflammation, autoimmunity and oncology.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Seed
Founded
2025
City
PARIS
Region
IDF
Tracked rounds
1
Amount raised
21 M€ raised since 2020

Funding rounds

  • Seed — 2026

Investors